A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors

Trial Profile

A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Elgemtumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
    • 18 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 12 Jan 2015 Planned End Date changed from 1 Jun 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top